The Barings LLC Has $516000 Stake in Chemours Company (The) (CC)

Institutional investors and hedge funds own 75.01% of the company's stock. Ameritas Investment Partners Inc. raised its position in Chemours Company (The) by 349.0% in the first quarter. Finally, UBS AG reissued a "sell" rating and issued a $36.00 price objective (up from $35.00) on shares of Chemours Company (The) in a report on Wednesday, June 14th. First American Bank acquired a new position in Chemours Company (The) during the first quarter valued at $262,000. BidaskClub lowered Chemours Company (The) from a "buy" rating to a "hold" rating in a research report on Saturday, June 17th.

Shares of Chemours Company (NYSE:CC) traded up 1.86% on Wednesday, hitting $43.74. A score above three means the company is not likely to go bankrupt, while score less than 1.8 suggests the firm is probably headed for bankruptcy. Finally, Susquehanna Bancshares Inc increased their price target on Chemours Company (The) from $45.00 to $55.00 and gave the company a "positive" rating in a research report on Monday, May 15th. The High end of the Estimate is $1.57 Billion, while the Low end of the Estimate is $1.47 Billion.

The Stock now has a consensus recommendation of 2.10.

4 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 1442.03 million while high and low sale targets are estimated at 1495.41 million and 1399 million respectively. J P Morgan Chase & Co raised shares of Chemours Company (The) from a neutral rating to an overweight rating and lifted their price objective for the company from $39.00 to $50.00 in a research note on Friday, May 12th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. The specialty chemicals company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.25. The Stock becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume.

The current market capitalization of Chemours Company (NYSE:CC) stands at 8.12 Billion. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company's stock valued at $119,000 after buying an additional 1,400 shares during the period.

The latest updates which have been released by analysts/brokers for Chemours (NYSE:CC) are outlined below. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company's stock valued at $737,696,000 after buying an additional 19,121,339 shares in the last quarter. The company had a trading volume of 1,864,132 shares. The specialty chemicals company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.25. Insiders have sold 46,725 shares of company stock valued at $1,919,300 in the last quarter. Schroder Investment Management Group bought a new position in shares of Chemours Company (The) during the first quarter worth $156,000. Chemours Company (The) had a return on equity of 125.69% and a net margin of 1.91%. During the same period past year, the business earned $0.06 earnings per share.

By having an overview of the Income statement for Chemours Company (NYSE:CC) the Revenue for the trailing twelve months is 5.54 Billion.

Quarterly Revenue growth year over year is 10.8 Percent. If you are reading this piece on another website, it was illegally copied and republished in violation of U.S. & global copyright laws. This represents a $0.12 annualized dividend and a dividend yield of 0.27%. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard H. Brown acquired 2,500 shares of the stock in a transaction dated Wednesday, May 3rd. The shares were bought at an average price of $39.10 per share, for a total transaction of $97,750.00. The disclosure for this purchase can be found here.

From another technical standpoint, The Chemours Company (NYSE:CC)'s 14-day Relative Strength Index (RSI) has reached 66.12, putting it inside a neutral zone.

CC's President - Fluoroproducts Kirsch Paul Sell 19036 shares of the company at a price of $41.42 on 2017-06-05. The Titanium Technologies segment is a producer of titanium dioxide (TiO2).

Want to see what other hedge funds are holding CC? The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.